Furthermore, benefits on ESRD, ESRD or death, and proteinuria in the losartan treatment group were maintained when hemoglobin decreased. Patients with lower hemoglobin (persistent anemia and new anemia) may be at greater risk for ESRD. A significant benefit of losartan treatment was seen for these populations.
ESRD มีข้อมูลพบว่าการให้ ACEI or ARB ช่วย preserve residual renal losartan คาดว่าไม่น่าจะส่งผลให้เกิด urate nephropathy มากขึ้นหรือ
Background Losartan is a selective angiotensin AT1 receptor antagonist currently employed in the management of essential hypertension. This compound is in common use in populations with renal failure and end-stage renal disease (ESRD). Objective To investigate the pharmacokinetics and pharmacodynamics of losartan in patients with ESRD in order to establish administration guidelines. Methods
Losartan significantly reduced the risk for the combined endpoint of end‐stage renal disease (ESRD), MI, stroke, or death by 21% (p 0.005), irrespective of whether all‐cause or cardiovascular death was included in the analysis. In addition, losartan reduced the risk for the composite of ESRD or cardiovascular death by 19.2% (p 0.05).
by WC Gerth 2024 Cited by 46Gerth et al: Losartan and ESRD costs. S-70. Table 2. RENAAL: Within-trial cumulative incidence of ESRD by duration of follow-up. Difference. Follow-up. Losartan.
Losartan significantly reduced the risk for the combined endpoint of end-stage renal disease (ESRD), MI, stroke, or death by 21% (p or = 0.005), irrespective of whether all-cause or cardiovascular death was included in the analysis. In addition, losartan reduced the risk for the composite of ESRD or cardiovascular death by 19.2% (p 0.05).
The pharmacokinetics of losartan and its active metabolite are linear with oral losartan doses up to 200 For the primary endpoint and ESRD, the effects of
by WKOK SENG 2024 Cited by 20Total cost, converted to US dollars, was the sum of ESRD and losartan costs. Results: Losartan plus CT reduced the number of days with ESRD by
Losartan reduced the incidence of doubling of serum creatinine, end-stage renal disease (ESRD), or death by 16% (P = 0.022) and reduced the risk of progression to ESRD, defined as the initiation of dialysis or transplantation, by 29% (P = 0.002).
Comments